Sexual function after surgery for prostate or bladder cancer

Cancer Control

Volumn 13, Issue 3, 2006, Pages 179-187

  Miranda Sousa, Alejandro J ^a   Davila, Hugo H ^a   Lockhart, Jorge L ^b   Ordorica, Raul C ^b   Carrion, Rafael E ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL; VASODILATOR AGENT;

ACNE; ANORGASMIA; BLADDER CANCER; BLADDER SURGERY; BLOOD VESSEL INJURY; CANCER SURGERY; CLINICAL TRIAL; CYSTECTOMY; DRUG MECHANISM; DRUG MEGADOSE; DYSPAREUNIA; ERECTILE DYSFUNCTION; FEMALE SEXUAL DYSFUNCTION; FIBROSIS; HIRSUTISM; HORMONAL THERAPY; HUMAN; HYPOXEMIA; LARYNX DISORDER; LIBIDO DISORDER; MALE SEXUAL DYSFUNCTION; ORGASM DISORDER; PATHOPHYSIOLOGY; PATIENT EDUCATION; PENIS PROSTHESIS; POSTOPERATIVE COMPLICATION; PRIAPISM; PROSTATE CANCER; PROSTATECTOMY; PSYCHOTHERAPY; REVIEW; SEX THERAPY; SEXUAL AROUSAL DISORDER; SEXUAL DYSFUNCTION; VIRILIZATION;

EID: 33749119101     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601300304     Document Type: Review

References (91)

1. Basson R, Berman J, Burnett A, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol. 2000;163:888-893.
2. World Health Organization: ICD-10: International Statistical Classification of Diseases and Related Health Problems. World Health Organization: Geneva; 1992.
3. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83-90.
4. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res. 2000;12(Suppl 4):S6-S11.
5. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537-544. Erratum in: JAMA. 1999;281:1174.
6. Dennerstein L, Randolph J, Taffe J, et al. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril. 2002;77(Suppl 4):S42-48.
7. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56;106-130.
8. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366-381.
9. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003;61:109-118; discussion 118.
10. Kamat AM, Lamm DL. Chemoprevention of urological cancer. J Urol. 1999;161:1748-1760.
11. Carrion R, Seigne J. Surgical management of bladder carcinoma. Cancer Control. 2002;9:284-292.
12. Lue TF, Takamura T, Schmidt RA, et al. Hemodynamics of erection in the monkey. J Urol. 1983;130:1237-1241.
13. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326:90-94.
14. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802-1813.
15. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191-236.
16. Kwan M, Greenleaf WJ, Mann J, et al. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab. 1983;57:557-562.
17. Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav. 1983;12:59-66.
18. Stief CG, Uckert S, Becker AJ, et al. The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J Urol. 1998;159:1390-1393.
19. De Luca V, Pescatori ES, Taher B, et al. Damage to the erectile function following radical pelvic surgery: prevalence of veno-occlusive dysfunction. Eur Urol. 1996;29:36-40.
20. User HM, Hairston JH, Zelner DJ, et al. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol. 2003;169:1175-1179.
21. Masters WH, Johnson VE. The sexual response cycle of the human female. III. The clitoris: anatomic and clinical consideration. West J Surg Obstet Gynecol. 1962;70:248-257.
22. Masters WH, Johnson VE. The sexual response of the human male. I. Gross anatomic considerations. West J Surg Obstet Gynecol. 1963;71:85-95.
23. Basson R. Female sexual response: the role of drugs in the management of sexual dysfunction. Obstet Gynecol. 2001;98:350-353.
24. Mah K, Binik YM. The nature of human orgasm: a critical review of major trends. Clin Psychol Rev. 2001;21:823-856.
25. Laan E, Everaerd W. Physiological measures of vaginal vasocongestion. Int J Impot Res. 1998;10(Suppl 2):S107-110; discussion S124-125.
26. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol. 1994;152(5 Pt 2):1831-1836.
27. Catalona WJ, Carvalhal GF, Mager DE, et al. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. 1999;162:433-438.
28. Rabbani F, Stapleton AM, Kattan MW, et al. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000;164:1929-1934.
29. Walsh PC. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. J Urol. 2000;164:242.
30. Jonler M, Messing EM, Rhodes PR, et al. Sequelae of radical prostatectomy. Br J Urol. 1994;74:352-358.
31. Fowler FJ, Jr., Barry MJ, Lu-Yao G, et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology. 1993;42:622-629.
32. Siegel T, Moul JW, Spevak M, Alvord WG, Costabile RA. The development of erectile dysfunction in men treated for prostate cancer. J Urol. 2001;165(2):430-435.
33. Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 1998;16:275-283.
34. Quinlan DM, Epstein JI, Carter BS, et al. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol. 1991;145:998-1002.
35. Leandri P, Rossignol G, Gautier JR, et al. Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urol. 1992;147(3 Pt 2):883-887.
36. Podlasek CA, Gonzalez CM, Zelner DJ, et al. Analysis of NOS isoform changes in a post radical prostatectomy model of erectile dysfunction. Int J Impot Res. 2001;13(Suppl 5):S1-15.
37. Bahnson RR, Catalona WJ. Papaverine testing of impotent patients following nerve-sparing radical prostatectomy. J Urol. 1988;139:773-774.
38. Breza J, Aboseif SR, Orvis BR, et al. Detailed anatomy of penile neurovascular structures: surgical significance. J Urol. 1989;141:437-443.
39. Droupy S, Hessel A, Benoit G, et al. Assessment of the functional role of accessory pudendal arteries in erection by transrectal color Doppler ultrasound. J Urol. 1999;162:1987-1991.
40. Fraiman MC, Lepor H, McCullough AR. Changes in penile morphometrics in men with erectile dysfunction after nerve-sparing radical retropubic prostatectomy. Mol Urol. 1999;3:109-115.
41. Iacono F, Giannella R, Somma P, et al. Histological alterations in cavernous tissue after radical prostatectomy. J Urol. 2005;173:1673-1676.
42. Nehra A, Goldstein I, Pabby A, et al. Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J Urol. 1996;156:1320-1329.
43. Klein LT, Miller MI, Buttyan R, et al. Apoptosis in the rat penis after penile denervation. J Urol. 1997;158:626-630.
44. Stenzl A, Colleselli K, Poisel S, et al. Rationale and technique of nerve sparing radical cystectomy before an orthotopic neobladder procedure in women. J Urol. 1995;154:2044-2049.
45. Stein JP, Esrig D, Freeman JA, et al. Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women. Urology. 1998;51:951-955.
46. Schoenberg M, Hortopan S, Schlossberg L, et al. Anatomical anterior exenteration with urethral and vaginal preservation: illustrated surgical method. J Urol. 1999;161:569-572.
47. Zippe CD, Raina R, Shah AD, et al. Female sexual dysfunction after radical cystectomy: a new outcome measure. Urology. 2004;63:1153-1157.
48. Horenblas S, Meinhardt W, Ijzerman W, et al. Sexuality preserving cystectomy and neobladder: initial results. J Urol. 2001;166:837-840.
49. Weijmar Schultz WC, Van De Wiel HB, Hahn DE, et al. Psychosexual functioning after treatment for gynecological cancer: an integrative model, review of determinant factors and clinical guidelines. Int J Gynecol Cancer. 1992;2:281-290.
50. Althof SE, Turner LA, Levine SB, et al. Through the eyes of women: the sexual and psychological responses of women to their partner's treatment with self-injection or external vacuum therapy. J Urol. 1992;147:1024-1027.
51. Rosen RC, Taylor JF, Leiblum SR, et al. Prevalence of sexual dysfunction in women: results of a survey study of 329 women in an outpatient gynecological clinic. J Sex Marital Ther. 1993;19:171-188.
52. Bjerre BD, Johansen C, Steven K. A questionnaire study of sexological problems following urinary diversion in the female patient. Scand J Urol Nephrol. 1997;31:155-160.
53. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338:1397-1404. Erratum in: N Engl J Med. 1998;339:59.
54. Kaplan SA, Reis RB, Kohn IJ, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology. 1999;53:481-486.
55. Caruso S, Intelisano G, Lupo L, et al. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG. 2001;108:623-628.
56. Muto G, Bardari F, D'Urso L, et al. Seminal sparing cystectomy and ileocapsuloplasty: long-term followup results. J Urol. 2004;172:76-80.
57. Colombo R, Bertini R, Salonia A, et al. Overall clinical outcomes after nerve and seminal sparing radical cystectomy for the treatment of organ confined bladder cancer. J Urol. 2004;171:1819-1822.
58. Burday D, Weber T, Thurman S, et al. Prostate-Sparing Radical Cystectomy: Erectile Function and Continence. J Urol. 2005;173:93.
59. Saidi A, Nahon O, Daniel L, et al. Prostate-sparing cystectomy: long-term functional and oncological results in a series of 25 cases. Prog Urol. 2004;14:172-177.
60. Sebe P, Traxer O, Cussenot O, et al. Cystectomy with preservation of the prostate in the treatment of bladder tumours: anatomical basis, surgical techniques, indications and results. Prog Urol. 2003;13:1279-1285.
61. Zhou FJ, Qin ZK, Han H, et al. Radical cystectomy with sparing partial prostate for invasive bladder cancer. Ai Zheng. 2003;22:1066-1069.
62. Meinhardt W, Horenblas S. Sexuality preserving cystectomy and neobladder (SPCN): functional results of a neobladder anastomosed to the prostate. Eur Urol. 2003;43:646-650.
63. Vallancien G, Abou El Fettouh H, Cathelineau X, et al. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol. 2002;168:2413-2417.
64. Carson C, Giuliano F, Goldstein I, et al. The 'effectiveness' scale - therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. Int J Impot Res. 2004;16:207-213.
65. Zippe CD, Jhaveri FM, Klein EA, et al. Role of Viagra after radical prostatectomy. Urology. 2000;55:241-245.
66. Zagaja GP, Mhoon DA, Aikens JE, et al. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology. 2000;56:631-634.
67. Feng MI, Huang S, Kaptein J, et al. Effect of sildenafil citrate on postradical prostatectomy erectile dysfunction. J Urol. 2000;164:1935-1938. Erratum in: J Urol. 2005;173:664.
68. Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol. 2003;170(4 Pt 1):1278-1283.
69. Montorsi F, Nathan HP, McCullough A, et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol. 2004;172:1036-1041.
70. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol. 2004;171 (2 Pt 1):771-774.
71. Valente EG, Vernet D, Ferrini MG, et al. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9:229-244.
72. Costabile RA, Spevak M, Fishman IJ, et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol. 1998;160:1325-1328.
73. Raina R, Agarwal A, Ausmundson S, et al. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res. 2005;17:86-90.
74. Montorsi F, Guazzoni G, Strambi LF, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol. 1997;158:1408-1410.
75. Marmar JL, DeBenedictis TJ, Praiss DE. The use of a vacuum constrictor device to augment a partial erection following an intracavernous injection. J Urol. 1988;140:975-979.
76. Baniel J, Israilov S, Segenreich E, et al. Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy. BJU Int. 2001;88:58-62.
77. Goldstein I, Bertero EB, Kaufman JM, et al. Early experience with the first pre-connected 3-piece inflatable penile prosthesis: the Mentor Alpha-1. J Urol. 1993;150:1814-1818.
78. Davis SR, McCloud P, Strauss BJ, et al. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995;21:227-236.
79. Kaiser FE. Sexuality in the elderly. Urol Clin North Am. 1996;23:99-109.
80. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343:682-688.
81. Lundberg PO, Hulter B. Sexual dysfunction in patients with hypothalamo-pituitary disorders. Exp Clin Endocrinol. 1991;98:81-88.
82. Davis SR, Burger HG. Clinical review 82: androgens and the postmenopausal woman. J Clin Endocrinol Metab. 1996;81:2759-2763.
83. Davis SR. The role of androgens and the menopause in the female sexual response. Int J Impot Res. 1998;10(Suppl 2):S82-83; discussion S98-101.
84. Basson R, McInnes R, Smith MD, et al. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med. 2002;11:367-377.
85. Padma-Nathan H, Brown C, Fendl J, et al. Efficacy and safety of topical alprostadil cream for the treatment of female sexual arousal disorder (FSAD): a double-blind, multicenter, randomized, and placebo-controlled clinical trial. J Sex Marital Ther. 2003;29:329-434.
86. Katz S, Morales AJ. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DS) as therapeutic options in menopause. Semin Reprod Endocrinol. 1998;16:161-170.
87. Crowe M, Jones M. Sex therapy: the successes, the failures, the future. Br J Hosp Med. 1992;48:474-479, 482.
88. Cartwright-Alcarese F. Addressing sexual dysfunction following radiation therapy for a gynecologic malignancy. Oncol Nurs Forum. 1995;22:1227-1232.
89. Gontero P, Kirby R. Proerectile pharmacological prophylaxis following nerve-sparing radical prostatectomy (NSRP). Prostate Cancer Prostatic Dis. 2004;7:223-226.
90. Mancini M, Bartolini M, Maggi M, et al. Duplex ultrasound evaluation of cavernosal peak systolic velocity and waveform acceleration in the penile flaccid state: clinical significance in the assessment of the arterial supply in patients with erectile dysfunction. Int J Androl. 2000;23:199-204.
91. Mancini M, Raina R, Agarwal A, et al. Sildenafil citrate vs intracavernous alprostadil for patients with arteriogenic erectile dysfunction: a randomised placebo controlled study. Int J Impot Res. 2004;16:8-12.